微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2026-09-30 | 71.27% | 79.59% | -7.14% | 34/159 | 50.44% | 迪哲医药 | 99.22% | 行业排名> |
| 2026-06-30 | 76.74% | 101.16% | 86.51% | 21/159 | 48.66% | 海创药业 | 97.34% | 行业排名> |
| 2026-03-31 | 41.15% | 3.07% | 7.23% | 91/159 | 50.28% | 海创药业 | 99.82% | 行业排名> |
| 2025-12-31 | 38.37% | -8.58% | -3.31% | 96/159 | 50.37% | 海创药业 | 98.62% | 行业排名> |
| 2025-09-30 | 39.68% | -7.7% | 4.01% | 92/159 | -2.13% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 38.15% | -12.87% | -4.43% | 97/159 | 15.05% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 39.92% | -14.53% | -4.89% | 93/159 | 31.79% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 41.97% | -8.9% | -2.37% | 99/159 | 51.61% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 42.99% | -9.87% | -1.81% | 90/159 | 22.43% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 43.79% | -7.66% | -6.25% | 90/159 | 32.96% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 46.71% | -4.47% | 1.37% | 82/159 | 51.47% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 46.07% | 6.63% | -3.41% | 92/159 | 51.31% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 47.7% | 10.4% | 0.59% | 83/159 | 32.31% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 47.42% | 9.06% | -3.01% | 87/159 | 38.22% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 48.89% | 8.9% | 13.15% | 78/159 | 52.66% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 43.21% | -1.14% | 0.01% | 96/159 | 53.51% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 43.2% | -15.02% | -0.63% | 91/159 | 5.67% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 43.48% | -17.45% | -3.15% | 93/159 | 20.91% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 44.89% | -22.8% | 2.72% | 81/159 | 54.06% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 43.71% | -21.47% | -14.03% | 92/159 | 54.9% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 50.84% | -11.23% | -3.48% | 71/159 | 46.49% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 52.67% | -7.61% | -9.42% | 74/159 | 46.97% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 58.15% | 12.98% | 4.49% | 54/159 | 53.79% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 55.66% | 8.48% | -2.82% | 67/159 | -147.51% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 57.27% | 9.87% | 0.45% | 56/159 | 56.06% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 57.01% | 10.33% | 10.76% | 56/159 | 53.85% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 51.47% | 3.18% | 0.32% | 60/159 | 54.83% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 51.31% | 4.52% | -1.57% | 72/159 | -1232.76% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 52.12% | 2% | 0.87% | 57/159 | 54.86% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 51.67% | 4.98% | 3.59% | 59/159 | 54.88% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 49.88% | 2% | 1.62% | 55/159 | 50.75% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 49.09% | 0.44% | -0.27% | 72/159 | -210.26% | 微芯生物 | 96.27% | 行业排名> |
| 2018-06-30 | 49.22% | 0.11% | 0.71% | 54/159 | 53.16% | 贝达药业 | 95.47% | 行业排名> |
| 2017-12-31 | 48.87% | 3.52% | -0.59% | 64/159 | 52.25% | 贝达药业 | 95.51% | 行业排名> |
| 2017-06-30 | 49.16% | 2% | 4.13% | 47/159 | 47.61% | 贝达药业 | 95.54% | 行业排名> |
| 2016-12-31 | 47.21% | 23.45% | 23.45% | 52/159 | 48.17% | 贝达药业 | 95.74% | 行业排名> |